Oral mezigdomide in combination with carfilzomib and dexamethasone demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to positive interim phase III results from the SUCCESSOR-2 study.
The Mount Sinai Tisch Cancer Center has entered a partnership with Cancer Hope Network to launch Peer Access to Trials, Hope and Support, a peer-to-peer program that gives patients and caregivers access to one-on-one peer mentorship from trained volunteers who have faced cancer themselves, either as survivors or caregivers.
